Choosing Between Surgery, Biologics, and Medical Management
For clinicians managing chronic rhinosinusitis (CRS), determining when to escalate treatment remains one of the more nuanced decisions in practice. While many patients achieve meaningful symptom control with topical therapies and intermittent medical management, others continue to struggle despite appropriate treatment, prompting consideration of surgery, biologic agents, or a combination of approaches.
Treatment selection extends beyond a simple algorithm. Inflammatory endotype, anatomic obstruction, comorbidities, prior treatment response, and patient preferences all shape the decision-making process. As evidence evolves, individualized strategies and multidisciplinary collaboration remain essential to optimizing outcomes.
Choosing Medical Management First
Some patients do surprisingly well with medical therapy alone. Saline rinses, nasal corticosteroid sprays, and occasional short courses of oral corticosteroids can reduce inflammation and improve quality of life. In some cases, a brief course of antibiotics may be added if there is evidence of bacterial infection. The AAFP guidelines highlight the value of starting conservatively while carefully monitoring response, a key step in refining CRS treatment decision-making.
The challenge lies in consistently monitoring for other symptoms such as recurring edema, polyp formation, or inflammatory biomarkers, which suggest additional therapy may be warranted. Chronic sinus therapy options should be investigated for their efficacy and potential reactions to a patient’s broader airway disease profile.
Sinus Surgery vs Biologics
Biologics have modified how we approach chronic sinusitis patients who are resistant to conventional treatment. Biologics such as dupilumab, omalizumab, and mepolizumab can reduce nasal polyps, improve airflow, and inform CRS treatment decision-making for type-2 inflammatory disease. Considering chronic sinus therapy options in conjunction with patient preferences and comorbidities supports an effective, whole-person approach that should also account for prior patient response to medications.
Patients with abnormal nasal anatomy or ongoing inflammation that limits response to medical therapy or biologics may benefit from functional endoscopic sinus surgery (FESS). Opening the sinus passages during FESS allows nasal sprays and irrigations to reach inflamed tissue more effectively, which improves the outcome of postoperative medical therapy.
Debates over sinus surgery vs biologics often hinge on the patient’s inflammatory profile and anatomic considerations. Surgery can directly remove obstructive tissue and restore airway flow while biologics target underlying type-2 inflammation. Choosing among chronic sinus therapy options requires consideration of immediate symptom relief, long-term disease control, and patient comorbidities, such as asthma or allergic rhinitis. Integrating clinical findings, prior treatment responses, and patient preferences allows CRS treatment decision-making to be patient specific for optimization of outcomes and patient satisfaction.
Combining CRS Treatment Collaboration Across Specialties
Some of the most complex cases benefit from a tiered approach, such as surgery followed by biologic therapy. Moreover, coordinating care among ENT, allergy, and pulmonology specialists allows CRS treatment decision-making to reflect the patient’s inflammatory profile, prior responses, and comorbidities as diagnosed by other doctors.
Deciding between sinus surgery vs biologics is rarely straightforward, and adjusting therapy usually requires combining interventions with ongoing topical treatments, close monitoring, and adaptive modifications. Specialists working together across disciplines supports more effective disease management and allows early-career clinicians to see CRS treatment decision-making in action as clinicians choose between surgery, biologics, and medical management.
The Future of Chronic Sinus Therapy Options
Advances in precision medicine continue to refine clinical approaches to chronic sinus disease, particularly for patients with complex inflammatory profiles. Registries and endotype profiling help identify which patients are most likely to benefit from surgery, biologics, or medical management, while mentoring new clinicians builds experience in interpreting these data. Additionally, evidence-based platforms and multi-center collaboration give teams the tools to evaluate the efficacy of sinus surgery vs biologics in more difficult cases.
Become part of the Snot Force network today to join cross‑discipline discussions, lead or contribute to research initiatives, and strengthen clinical practice for complex airway care.
